175 related articles for article (PubMed ID: 27939143)
1. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
[TBL] [Abstract][Full Text] [Related]
2. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
[TBL] [Abstract][Full Text] [Related]
3. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Absar S; Choi S; Yang VC; Kwon YM
J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
Birnbaum Y; Atar S; Luo H; Nagai T; Siegel RJ
Thromb Res; 1999 Dec; 96(6):451-8. PubMed ID: 10632468
[TBL] [Abstract][Full Text] [Related]
5. Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage.
Zhang L; Luo H; Li C; Teng H; Powell B; Lu M; Chopp M; Zhang ZG
Front Neurol; 2023; 14():1282736. PubMed ID: 37869138
[TBL] [Abstract][Full Text] [Related]
6. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Traumatic Brain Injury with Vepoloxamer (Purified Poloxamer 188).
Zhang Y; Chopp M; Emanuele M; Zhang L; Zhang ZG; Lu M; Zhang T; Mahmood A; Xiong Y
J Neurotrauma; 2018 Feb; 35(4):661-670. PubMed ID: 29121826
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
10. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
Wikström K; Mattsson C; Pohl G
Thromb Res; 1993 May; 70(3):217-24. PubMed ID: 8392227
[TBL] [Abstract][Full Text] [Related]
11. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
12. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
Valji K; Bookstein JJ
Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201
[TBL] [Abstract][Full Text] [Related]
13. Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis.
Sharifi M; Bay C; Nowroozi S; Bentz S; Valeros G; Memari S
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1586-1590. PubMed ID: 23377239
[TBL] [Abstract][Full Text] [Related]
14. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model.
Myers DD; Henke PK; Wrobleski SK; Hawley AE; Farris DM; Chapman AM; Knipp BS; Thanaporn P; Schaub RG; Greenfield LJ; Wakefield TW
J Vasc Surg; 2002 Nov; 36(5):928-38. PubMed ID: 12422103
[TBL] [Abstract][Full Text] [Related]
15. Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis.
Röttger C; Madlener K; Heil M; Gerriets T; Walberer M; Wessels T; Bachmann G; Kaps M; Stolz E
Stroke; 2005 Apr; 36(4):841-6. PubMed ID: 15731475
[TBL] [Abstract][Full Text] [Related]
16. Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.
Atar S; Neuman Y; Miyamoto T; Chen M; Birnbaum Y; Luo H; Kobal S; Siegel RJ
J Thromb Thrombolysis; 2003 Jun; 15(3):165-9. PubMed ID: 14739625
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Vogel GM; Lormeau JC; Petitou M; Meuleman DG
Circ Res; 1996 Sep; 79(3):590-600. PubMed ID: 8781492
[TBL] [Abstract][Full Text] [Related]
18. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
[TBL] [Abstract][Full Text] [Related]
19. Visualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy.
Walvick RP; Bråtane BT; Henninger N; Sicard KM; Bouley J; Yu Z; Lo E; Wang X; Fisher M
Stroke; 2011 Apr; 42(4):1110-5. PubMed ID: 21372305
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3Kγ by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Jin R; Zhong W; Liu S; Wang M; Li G
Neurosci Lett; 2020 Nov; 738():135339. PubMed ID: 32882317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
